Potential of combination therapy in patients with hypertension and dyslipidemia

Abstract

This article provides an overview of data on the role of hypertension and dys-lipidemia as the leading factors determining the clinical course of atherosclerotic diseases. The need for a multifactorial approach to the treatment of patients with multiple risk factors for the progression of such diseases is noted. The article describes the results of large-scale international studies confirming the clinical benefits of combined antihypertensive and lipid-lowering therapy. From the point of view of current clinical guidelines and the available evidence base, the potential for improving adherence to treatment using a combination of antihypertensive and lipid-lowering drugs are presented. The article discusses the prospects for optimizing the therapy of comorbid patients using a triple fixed-dose combination, including amlodipine, atorvastatin and perindopril.